Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

Karyopharm said abstracts from two myelofibrosis trials of selinexor were selected for oral presentation at ASH 2026, including Phase 3 SENTRY data through week 48; the release provides no new numerical efficacy results. The company’s Chapter 11 notice says its plan provides no distribution to common or preferred shareholders and that existing equity is expected to have no value, with a complete investment loss for holders. The company also described early SENTRY-2 data as supporting selinexor monotherapy activity in JAK-inhibitor-naïve patients.

Analysis

The key valuation distinction is between the clinical asset and the listed common equity. Even favorable myelofibrosis data could improve the perceived value of selinexor or strengthen a successor’s development case, but that value does not automatically accrue to KPTI shareholders: the release says the Chapter 11 plan provides no distribution to common equity and the company expects existing equity to be worthless. Treat the ASH presentations as potential estate/restructuring catalysts, not a conventional biotech read-through.

Over the next few days, the financing and restructuring overhang dominates any abstract-selection sentiment. On the December 12–13 data releases, the relevant questions are durability, tolerability, and whether results are sufficiently differentiated to preserve development value. At 6–18 months, continuity of trials, supplier and partner support, and the successor’s ability to fund development matter more than the current issuer’s commercial footprint. In myelofibrosis, a credible selinexor profile could raise competitive pressure on established JAK-inhibitor approaches, but this release supplies no new efficacy or safety results to establish a change in treatment practice.

Contrarian point: the announcement may look like pipeline validation, yet it may be equity-negative in practical terms if it distracts from the recovery waterfall or invites speculative trading in a security explicitly facing a zero recovery. Falsifiers are a material change to the confirmed restructuring plan or recovery treatment for common holders; absent that, clinical upside alone does not overturn the equity thesis.

Key Decisions for Investors

• Do not buy KPTI common on the ASH announcement; underwrite the confirmed Chapter 11 plan and recovery waterfall, not the clinical narrative. Revisit only if court-approved restructuring terms materially change common-equity treatment.
• Avoid an outright short as a routine expression of the thesis: distressed, low-float trading and restructuring headlines can create violent squeezes, while borrow and execution conditions may be unreliable. No options position is warranted from abstract selection alone.
• Watch the December presentations for independently assessable response durability, symptom benefit, adverse-event burden, and subgroup detail. These data could affect the value of the drug program or successor, but are not themselves evidence of value for current common shareholders.
• Alert for court filings, plan confirmation, delisting timing, and disclosures on trial and supplier continuity. Any change in equity recovery terms or a funded successor agreement would require reassessing the security-level conclusion.